Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.65), $0.06 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $2.4 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.